Company Overview and News

 
Shalimar Paints Limited - Shareholders meeting

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

 
Shalimar Paints Limited - Shareholders meeting

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

 
Podcast | Digging Deeper - Shalimar Paints explores options amid shifting business scenarios

2018-08-27 moneycontrol
The advertising catchphrase for Shalimar Paints is ‘Rang Desh Ka’ and for a good reason but more about that later. A recent report in the Economic Times said that the company, older than the Republic of India, is exploring various fundraising opportunities including investment from third parties or strategic investor to improve its performance.
500820 SHALPAINTS ASIANPAINT 509874

 
Shalimar Paints Limited - Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

 
SBI, NHPC, Hindalco, Sun TV, PC Jeweller, results

2018-08-09 thehindubusinessline
Andhra Bank, Apollo Hospitals, Allcargo Logistics, Bosch, DLF, Dr Lal Path, Deep Industries, GAIL, GE Shipping, Glenmark Pharma, Hindalco, Indian Hotels, JB Chemicals, Kirloskar Oil, Max India, Max Ventures, NCC, NHPC, PC Jeweller, Puravankara, STCI, State Bank of India, Sun TV, Shalimar Paints, Uflex, Union Bank of India, UCO Bank, United Breweries, Vakrangee, Voltas and Wanbury are among over 180 companies that will declare their April-June results on Friday.
UBNC SHALPAINTS UBL 532749 UBHOLDINGS 532418 532505 UNBWY 532478 DEEPIND 500271 532760 ALLCARGO 500850 534809 MAX PCJEWELLER UCOBANK INDHOTEL 507458 509874 MXGQY ANDHRABANK SBAZ

 
Shalimar Paints Limited - Updates

2018-07-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 freepressjournal.in
New Delhi: Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER HINDUNILVR 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 500696 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Footwear, paint, consumer durables, FMCG stocks surge up to 10% on GST rate cut

2018-07-23 thehindubusinessline
Shares of footwear, paint makers, consumer durables and FMCG companies surged up to 10 per cent today after the GST Council reduced tax rates on a number of products.
LIBERTSHOE 517421 500820 SHALPAINTS 530517 KAJARIACER 532953 ASIANPAINT MIRZAINT RELAXO VGUARD 500233 526642 500031 517354 500710 HVLQY 505726 KNZAY BATAINDIA KANSAINER AKZOINDIA HAVELLS IFBIND BUTTERFLY 526596 500043 509874 BAJAJELEC 500165

 
Shalimar Paints surges 10% as board approves rights issue upto Rs 240cr

2018-07-11 moneycontrol
Shares of Shalimar Paints surged 10.5 percent intraday Wednesday as company approved rights issue worth Rs 240 crore.
SHALPAINTS 509874

 
Shalimar Paints Limited - Shareholders meeting

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

 
US-China trade war tensions to take centre stage in coming week; These 3 stocks to be in focus

2018-07-08 moneycontrol
The upcoming week will be important for the market as developments around imposition of US-China tariffs are likely to stay in focus through the week.
BAJAJ-AUTO KESORAMIND SHALPAINTS 532418 KTKBANK 532218 532977 SOUTHBANK 532187 INOXWIND HEROMOTOCO 500231 502937 INDUSINDBK VTUWY 533269 500182 532652 532210 ONP UMANGDAIR CUB HRTQY 539083 509874 KRIDF WABAG ANDHRABANK

 
Shalimar Paints Limited - Updates

2018-07-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SHALPAINTS 509874

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...